A month has gone by since the last earnings report for AngioDynamics (
ANGO Quick Quote ANGO - Free Report) . Shares have lost about 12.1% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is AngioDynamics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
AngioDynamics Q1 Earnings and Revenues Top Estimates
AngioDynamics, Inc. reported first-quarter fiscal 2021 adjusted earnings per share of 2 cents against the Zacks Consensus Estimate of a loss per share of 6 cents. The company saw a decline of 75% in its bottomline from the year-ago quarter.
For the fiscal first quarter, revenues totaled $70.2 million, which beat the Zacks Consensus Estimate by 6.9%. Further, the top line rose 6.3% on a year-over-year basis.
In the quarter under review, U.S. net revenues totaled $54.1 million, up 2.2% year over year.
International revenues came in at $16.1 million, up 22.9% from the year-ago quarter.
Segmental Analysis Vascular Interventions and Therapies (VIT) Business
VIT revenues in the fiscal first quarter grossed $29.9 million, up 3.3% from the year-ago quarter. This was driven by 46% growth in AngioVac sales, partially offset by a decline in sales of Venous products due to a drop in elective procedure volumes.
Vascular Access (VA) Business
Revenues at this segment amounted to $28.1 million, up 21.4% on a year-over-year basis.
Revenues at the Oncology segment declined 12.3% year over year to $12.3 million. Per management,growth in microwave ablation and U.S. NanoKnife probe sales was more than offset by lower sales in overseas markets.
In the quarter under review, gross profit totaled $35.8 million, down 6.4% from the year-ago quarter number. Moreover, gross margin was 50.9%, down 693 basis points (bps).
Adjusted operating profit came in at $18.2 million, down 22.5% year over year. Adjusted operating margin came at 25.9%, highlighting a contraction of 962 bps.
Revenues are expected in the range of $278-$284 million. The Zacks Consensus estimate for the same is pegged at $274.1 million.
Adjusted earnings per share is estimated between a breakeven and 5 cents. The Zacks Consensus estimate for the metric is pegged at a loss of 11 cents.
The company exited the fiscal first quarter with $47.9 million of cash and cash equivalents, compared with $54.4 million at the end of the fourth quarter of fiscal 2020. Net cash used in operating activities came in at $5.4 million versus $6.5 million a year ago.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision flatlined during the past month. The consensus estimate has shifted 42.86% due to these changes.
Currently, AngioDynamics has a subpar Growth Score of D, however its Momentum Score is doing a bit better with a C. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
AngioDynamics has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.